PDI client won’t renew $35 million deal

Share this article:
Contract sales firm PDI said a “large pharmaceutical company” client has decided not to renew a $35 million contract sales engagement with the firm. PDI said it had expected the one-year deal, which expires May 12, to be extended through the end of 2007. The loss of the deal, announced yesterday, is just the latest in a series of contract setbacks for PDI. In October, GlaxoSmithKline decided not to renew its 2007 sales agreement with PDI. That deal represented as much as $70 million in annual revenue for the contract sales firm. Also in October, Sanofi-Aventis ended a $20 million sales engagement with PDI. And in March 2006, AstraZeneca discontinued its fee-for-service agreements with PDI, after previously working with the firm for 12 years. That termination affected approximately 800 field representatives and impacted $65 to $70 million of PDI’s revenue. PDI CEO Michael Marquad called the latest setback “disappointing” in a statement, adding that it “underscores the importance of our strategy, which focuses on diversifying our revenue stream.” Marquad added that PDI would continue to be engaged in discussions with other large pharma companies for fee-for-service contracts, while exploring potential acquisition opportunities.
Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.